Intervention not reported
Treatment discontinuation due to adverse event (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention probably leads to lower treatment discontinuation due to adverse event (safety population) (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related death (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher treatment‐related death (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Nausea/vomiting* grade 3 or 4 (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher nausea/vomiting* grade 3 or 4 (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Nephrotoxicity (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Anaemia grade 3 or 4 (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher anaemia grade 3 or 4 (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Hair loss (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to lower hair loss (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Leukopaenia (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention probably leads to higher leukopaenia (safety population) (moderate certainty).
1 finding from 1 review
Intervention not reported
Any reported infant death (fetal, neonatal, or before hospital discharge · pregnant women considered to be at risk of developing pre‐eclampsia
The intervention leads to lower any reported infant death (fetal, neonatal, or before hospital… (high certainty).
1 finding from 1 review
Safety of MSC infusion · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
1 finding from 1 review
Safety of the intervention (adverse effects) · non‐small cell lung cancer
1 finding from 1 review
Fetal/neonatal/infant · women with mild to moderate hypertension during pregnancy
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Total reported fetal or neonatal deaths (including miscarriage) · women with mild to moderate hypertension during pregnancy
Any antihypertensive drug showed no clear difference in total reported fetal or neonatal deaths (including miscarriage) compared with no antihypertensive drugs/placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse effects experienced by mother and/or fetus or nursing baby · women with a history of postnatal depression
1 finding from 1 review
Home visit with encouragement to receive influenza vaccination compared to home visit with safety intervention · people aged 60 years and older living in the community
Enhancing vaccination access showed no clear difference in home visit with encouragement to receive influenza vaccination… compared with no intervention or another intervention (high certainty).
1 finding from 1 review
Lisdexamfetamine · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abnormal fetal heart rate patterns, requiring intervention · women in the second stage of labour with epidural anaesthesia
It is very uncertain whether upright position changes abnormal fetal heart rate patterns, requiring intervention compared with recumbent position (very low certainty).
1 finding from 1 review
Safety Any serious adverse event · patients with fibromyalgia
It is very uncertain whether serotonin noradrenaline reuptake inhibitors changes safety (serious adverse events) compared with placebo (very low certainty).
1 finding from 1 review
Live birth rate · Women undergoing IVF/ICSI cycles
Metabolomics showed no clear difference in live birth rate (Delivery of a live fetus after 20 completed weeks… compared with non metabolomics (low certainty).
1 finding from 1 review
Live birth or ongoing pregnancy · Women undergoing IVF/ICSI cycles
Metabolomics showed no clear difference in live birth rate or ongoing pregnancy (Delivery of a live fetus after… compared with non metabolomics (low certainty).
1 finding from 1 review
Clinical pregnancy (Presence of a fetal heart on ultrasound scan at seven weeks of gestation) · Women undergoing IVF/ICSI cycles
Metabolomics showed no clear difference in clinical pregnancy (Presence of a fetal heart on ultrasound scan at… compared with non metabolomics (low certainty).
1 finding from 1 review